Skip to NavigationSkip to content

Pfizer's palbociclib most commonly used breast cancer drug in clinical trials

Published on 11/12/18 at 11:00am

Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.

The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.

Mohamed Abukar, Pharma Analyst at GlobalData, commented: “The vast majority of trials investigating palbociclib use combination therapy (83%) to assess progression-free survival. The tubulin inhibitor paclitaxel was investigated in 3.5% of clinical trials, primarily in combination regimens; only 6.3% of clinical trials investigate the agent as monotherapy, and involved comparing different routes of administration.”

Meanwhile 10.9% of all oncology trials were related to breast cancer between 1 January 2018 and 16 November 2018.

Overall, the majority of clinical trials were in Phase II (50.8%) while the US led in regards to the quantity of clinical trials they conducted with 22.4% of trials being done in United States.  In comparison China, who came in second place, conducted 10.6% of clinical trials.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches